Generic Drug Stems, Labs, and Supportive Care Patterns
Key Takeaways
- ONCC uses generic drug names only, so final review should emphasize generic names, suffix patterns, mechanisms, and toxicity clusters.
- Drug stems help with recognition but do not replace knowing route, indication, monitoring, and patient-specific risk.
- Lab review should focus on patterns that change nursing assessment, escalation, education, and treatment readiness.
- Supportive care questions often test prevention and early reporting of infection, bleeding, dehydration, mucositis, neuropathy, nausea, diarrhea, constipation, and pain.
- Final-week pharmacology review should connect each drug or class to one or two decisive safety issues.
Generic Drug Stems, Labs, and Supportive Care Patterns
Review generic names only
ONCC tests use generic drug names only. In final review, remove brand-name-only flashcards from your main deck and convert them to generic names. A brand may help you recognize a medication in practice, but the exam stem will not depend on it. Build your last-week drug review around class, mechanism clue, common route, signature toxicities, and nursing action.
High-yield generic name clues
| Name clue | Common meaning | Nursing review focus |
|---|---|---|
| -mab | Monoclonal antibody | Infusion reactions, immune effects, target-specific toxicities |
| -nib | Kinase inhibitor | Oral adherence, interactions, rash, diarrhea, hypertension, liver tests |
| -parib | PARP inhibitor | Cytopenias, fatigue, nausea, reproductive precautions |
| -zomib | Proteasome inhibitor | Neuropathy, thrombocytopenia, infection risk, antiviral prophylaxis if ordered |
| -ciclib | CDK inhibitor | Neutropenia, diarrhea or liver monitoring depending on agent |
| Name clue | Common meaning | Nursing review focus |
|---|---|---|
| -platin | Platinum chemotherapy | Nausea, nephrotoxicity, ototoxicity, neuropathy, hypersensitivity risk |
| -taxel | Taxane chemotherapy | Hypersensitivity, neuropathy, myelosuppression, alopecia |
| -rubicin | Anthracycline | Cardiotoxicity, vesicant risk, myelosuppression, lifetime dose awareness |
Stems are clues, not guarantees. Some agents have unique risks that do not fit a simple suffix rule. If a practice question includes a drug name you only partly recognize, use the stem to narrow the likely class, then return to the patient problem in the stem.
Lab patterns worth drilling
| Lab or pattern | Why it matters for OCN decisions |
|---|---|
| Low ANC | Infection risk, fever precautions, possible urgent neutropenic fever workup |
| Low platelets | Bleeding precautions, fall risk, procedure risk, patient teaching |
| Low hemoglobin | Fatigue, dyspnea, activity tolerance, transfusion assessment if ordered |
| Rising creatinine | Hydration, nephrotoxic therapy risk, dose-readiness concern |
| Elevated liver tests | Hepatotoxicity, immune hepatitis, obstruction, treatment readiness |
| Hyperkalemia | Tumor lysis or kidney injury risk; cardiac monitoring concern |
| Lab or pattern | Why it matters for OCN decisions |
|---|---|
| Hypocalcemia with high phosphate | Tumor lysis pattern |
| Hypercalcemia | Dehydration, weakness, constipation, confusion, fall risk |
| Abnormal glucose or thyroid tests | Possible endocrine toxicity with immunotherapy |
Do not memorize labs as isolated numbers only. The exam is more likely to ask what the nurse should assess, teach, report, or prioritize. Pair each abnormal result with symptoms and context. A potassium concern after high-risk leukemia therapy is different from a stable chronic abnormality already addressed by the team.
Supportive care pattern table
| Problem | Assessment focus | Teaching focus |
|---|---|---|
| Nausea and vomiting | Intake, hydration, timing, antiemetic use | Take prescribed antiemetics correctly; call for uncontrolled symptoms |
| Diarrhea | Frequency over baseline, blood, fever, dizziness | Hydration, report severe or persistent diarrhea, avoid self-treatment when high risk |
| Constipation | Opioids, intake, bowel pattern, obstruction symptoms | Bowel regimen as prescribed, fluids if allowed, call for severe pain or vomiting |
| Problem | Assessment focus | Teaching focus |
|---|---|---|
| Mucositis | Oral intake, pain, infection, bleeding | Oral care, avoid irritants, report inability to drink or fever |
| Neuropathy | Falls, fine motor changes, pain, gait | Safety, report worsening symptoms before injury |
| Fatigue | Reversible causes, sleep, anemia, distress | Energy conservation, activity balance, report severe change |
| Pain | Location, quality, severity, function, adverse effects | Scheduled and breakthrough use, constipation prevention, safe storage |
Final-week drug review method
For each drug or class, write one line: generic name, class clue, signature toxicity, and urgent teaching point. Example: paclitaxel, taxane, hypersensitivity and neuropathy, report dyspnea or chest tightness during infusion. Example: doxorubicin, anthracycline, cardiotoxicity and vesicant injury, report swelling or burning at IV site. Example: pembrolizumab, monoclonal antibody checkpoint inhibitor, immune-related organ inflammation, report diarrhea, cough, severe fatigue, rash, or jaundice early.
Avoid common traps
Do not choose an answer that tells a patient to wait out fever during neutropenia. Do not normalize new dyspnea on immunotherapy. Do not teach patients to stop oral therapy permanently without contacting the oncology team. Do not recommend herbal supplements as a substitute for evidence-based symptom management. Do not let a familiar drug name distract you from a new safety problem in the stem.
The final review target is not encyclopedic pharmacology. It is fast recognition of the drug class, the danger signal, and the nursing response that keeps the patient safe.
Why should final OCN drug review emphasize generic names?
A drug ending in -parib most strongly suggests which review focus?
Which lab pattern is most consistent with tumor lysis syndrome risk?